Your browser is no longer supported. Please, upgrade your browser.
NVRO Nevro Corp. daily Stock Chart
Nevro Corp.
Index- P/E- EPS (ttm)-3.01 Insider Own1.80% Shs Outstand33.99M Perf Week-2.98%
Market Cap4.91B Forward P/E- EPS next Y-1.65 Insider Trans-17.33% Shs Float32.68M Perf Month8.25%
Income-97.50M PEG- EPS next Q-0.59 Inst Own- Short Float7.30% Perf Quarter17.96%
Sales358.40M P/S13.69 EPS this Y-105.60% Inst Trans10.72% Short Ratio7.67 Perf Half Y54.62%
Book/sh11.02 P/B12.81 EPS next Y43.60% ROA-18.30% Target Price154.55 Perf Year60.77%
Cash/sh16.18 P/C8.72 EPS next 5Y25.00% ROE-38.90% 52W Range65.05 - 148.63 Perf YTD20.10%
Dividend- P/FCF- EPS past 5Y-22.10% ROI-26.00% 52W High-5.02% Beta0.85
Dividend %- Quick Ratio2.80 Sales past 5Y64.30% Gross Margin70.00% 52W Low117.02% ATR4.98
Employees853 Current Ratio3.20 Sales Q/Q-39.70% Oper. Margin-24.00% RSI (14)53.29 Volatility3.33% 3.79%
OptionableYes Debt/Eq0.81 EPS Q/Q-32.30% Profit Margin-27.20% Rel Volume0.94 Prev Close144.43
ShortableYes LT Debt/Eq0.37 EarningsAug 05 AMC Payout- Avg Volume311.28K Price141.17
Recom1.80 SMA200.74% SMA504.04% SMA20014.95% Volume293,742 Change-2.26%
Sep-02-20Initiated Robert W. Baird Outperform $160
Jun-08-20Upgrade UBS Sell → Neutral $100 → $132
Mar-05-20Initiated Citigroup Buy $160
Feb-26-20Upgrade Canaccord Genuity Hold → Buy $153
Jan-08-20Initiated SunTrust Buy $132
Jan-06-20Downgrade Oppenheimer Outperform → Perform
Nov-07-19Upgrade Oppenheimer Perform → Outperform $106
Oct-22-19Initiated Oppenheimer Perform
Mar-20-19Upgrade Wells Fargo Market Perform → Outperform $75
Mar-20-19Upgrade BofA/Merrill Neutral → Buy $50 → $70
Nov-28-18Initiated UBS Sell
Nov-07-18Downgrade BofA/Merrill Buy → Neutral
Nov-06-18Downgrade Morgan Stanley Equal-Weight → Underweight
Nov-06-18Downgrade JP Morgan Overweight → Neutral
Oct-19-18Downgrade Goldman Neutral → Sell
Jul-02-18Downgrade Morgan Stanley Overweight → Equal-Weight
May-08-18Reiterated Canaccord Genuity Buy $110 → $102
May-08-18Downgrade Wells Fargo Outperform → Market Perform
May-08-18Downgrade Northland Capital Outperform → Market Perform
Apr-04-18Initiated Goldman Neutral $83
Sep-23-20 06:43PM  
Sep-21-20 01:25PM  
Sep-17-20 09:30AM  
Sep-14-20 07:00AM  
Sep-10-20 10:11AM  
Sep-08-20 06:51AM  
Sep-04-20 11:31AM  
Sep-01-20 07:00AM  
Aug-26-20 01:27PM  
Aug-07-20 07:20AM  
Aug-06-20 01:24PM  
Aug-05-20 05:45PM  
Jul-31-20 10:54AM  
Jul-29-20 12:33PM  
Jul-20-20 07:00AM  
Jul-13-20 04:17PM  
Jul-10-20 08:46AM  
Jun-13-20 08:59AM  
Jun-08-20 12:33PM  
Jun-05-20 10:31AM  
Jun-04-20 11:31AM  
May-27-20 06:24AM  
May-18-20 06:59AM  
May-14-20 07:00AM  
May-07-20 09:14AM  
May-06-20 08:04AM  
May-05-20 07:25PM  
Apr-28-20 12:33PM  
Apr-21-20 07:00AM  
Apr-09-20 12:42PM  
Apr-08-20 10:17PM  
Apr-03-20 04:44PM  
Apr-02-20 08:00AM  
Apr-01-20 04:40PM  
Mar-27-20 03:50PM  
Mar-26-20 11:30AM  
Mar-22-20 11:03AM  
Mar-11-20 08:50AM  
Feb-28-20 08:45AM  
Feb-27-20 11:12AM  
Feb-26-20 09:21AM  
Feb-25-20 05:35PM  
Feb-24-20 08:35AM  
Feb-21-20 10:20AM  
Feb-13-20 08:16AM  
Feb-10-20 09:47AM  
Feb-07-20 10:52AM  
Feb-04-20 09:16AM  
Jan-22-20 07:00AM  
Jan-20-20 10:07AM  
Jan-16-20 10:14AM  
Jan-14-20 07:00AM  
Jan-10-20 07:00AM  
Dec-31-19 06:37AM  
Dec-26-19 10:06AM  
Dec-20-19 03:28PM  
Dec-19-19 07:00AM  
Dec-18-19 07:00AM  
Dec-06-19 01:16PM  
Nov-08-19 09:33AM  
Nov-07-19 10:09PM  
Nov-06-19 07:35PM  
Nov-05-19 07:00AM  
Oct-30-19 10:33AM  
Oct-25-19 10:12AM  
Oct-10-19 07:00AM  
Oct-08-19 10:10AM  
Sep-23-19 11:09AM  
Sep-07-19 09:30AM  
Aug-28-19 07:00AM  
Aug-23-19 07:00AM  
Aug-19-19 09:14AM  
Aug-15-19 02:24PM  
Aug-13-19 09:08AM  
Aug-10-19 01:11AM  
Aug-09-19 09:45AM  
Aug-08-19 04:10PM  
Aug-01-19 10:32AM  
Jul-25-19 07:00AM  
Jul-15-19 04:30PM  
Jul-02-19 09:00AM  
Jun-25-19 07:00AM  
Jun-21-19 10:45AM  
Jun-14-19 07:24AM  
Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. It also offers Senza II system and Senza Omnia system products for chronic pain. The company's solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. Nevro Corp. sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was founded in 2006 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DEMANE MICHAEL FDirectorSep 16Sale146.5616,0282,349,041257,440Sep 17 05:36 PM
DEMANE MICHAEL FDirectorSep 15Sale145.272,000290,546273,468Sep 17 05:36 PM
Pellegrini Niamh LouiseChief Commercial OfficerSep 10Option Exercise64.9575048,71334,895Sep 14 04:06 PM
Pellegrini Niamh LouiseChief Commercial OfficerSep 10Sale139.14750104,35534,145Sep 14 04:06 PM
DEMANE MICHAEL FDirectorSep 02Sale145.253,400493,864275,468Sep 04 04:14 PM
DEMANE MICHAEL FDirectorAug 27Sale141.0118,9002,665,004278,868Aug 31 07:15 PM
DEMANE MICHAEL FDirectorAug 13Sale140.0530042,016347,768Aug 17 04:41 PM
Pellegrini Niamh LouiseChief Commercial OfficerAug 10Option Exercise64.9575048,71334,895Aug 10 06:55 PM
Pellegrini Niamh LouiseChief Commercial OfficerAug 10Sale140.11750105,08334,145Aug 10 06:55 PM
DEMANE MICHAEL FDirectorAug 10Sale135.634,500610,35338,054Aug 12 04:32 PM
DEMANE MICHAEL FDirectorAug 10Sale135.6883,44011,321,141348,068Aug 12 04:32 PM
McCormick ShawnDirectorMay 21Sale126.501,020129,0307,772May 26 02:31 PM
Schmitz PatrickVice President, OperationsFeb 28Option Exercise66.7542,8842,862,58161,542Mar 03 02:49 PM
Galligan Andrew HChief Financial OfficerFeb 28Option Exercise3.608,00028,80061,490Mar 03 02:48 PM
Schmitz PatrickVice President, OperationsFeb 28Sale128.7842,8845,522,57418,658Mar 03 02:49 PM
Galligan Andrew HChief Financial OfficerJan 08Option Exercise63.2317,7181,120,30971,208Jan 10 06:59 PM
Galligan Andrew HChief Financial OfficerJan 08Sale120.1117,7182,128,08653,490Jan 10 06:59 PM
Galligan Andrew HChief Financial OfficerJan 06Option Exercise63.232,782175,90656,272Jan 08 12:00 PM
Galligan Andrew HChief Financial OfficerJan 06Sale120.002,782333,84053,490Jan 08 12:00 PM
Galligan Andrew HChief Financial OfficerNov 25Option Exercise63.2312,000758,76065,490Nov 26 04:23 PM
Galligan Andrew HChief Financial OfficerNov 25Sale110.3912,0001,324,71453,490Nov 26 04:23 PM
Alleavitch DougVP, QualityNov 25Sale110.001,000110,00024,073Nov 26 04:22 PM
Galligan Andrew HChief Financial OfficerNov 11Option Exercise47.3018,522876,15672,012Nov 13 07:20 PM
McCormick ShawnDirectorNov 11Sale104.3580083,4807,416Nov 13 07:23 PM
DEMANE MICHAEL FDirectorNov 11Sale103.7050,0005,185,163429,519Nov 13 07:21 PM
Galligan Andrew HChief Financial OfficerNov 11Sale103.7018,5221,920,73153,490Nov 13 07:20 PM
Alleavitch DougVP, QualityNov 07Sale100.001,000100,00025,073Nov 08 06:20 PM